RA0192

antibody from Oursmab

Targeting: EGFL7 ZNEU1

Western blot (Supportive data in Antibodypedia)

ELISA (Supportive data in Antibodypedia)

Immunocytochemistry (Recommended by provider)

Flow cytometry (Recommended by provider)

Functional assay (Recommended by provider)

Antibody Data

Product number

RA0192

Provider

Oursmab

Product name

Parsatuzumab (Biosimilar Reference Antibody) (EGFL7)

Antibody type

Monoclonal

Description

Parsatuzumab is a humanized IgG1-kappa monoclonal antibody that targets epidermal growth factor-like domain 7 (EGFL7), a secreted protein predominantly expressed by endothelial cells during vascular development and tumor angiogenesis. By binding to EGFL7, it selectively blocks the interaction between EGFL7 and endothelial cells, thereby inhibiting angiogenesis (the formation of new blood vessels). Additionally, it modulates vascular endothelial growth factor (VEGF) activity, further suppressing tumor vasculature. As an immunomodulator, it may also influence the tumor microenvironment. It was developed as an anti-angiogenic agent for the treatment of advanced solid tumors, with clinical studies focusing on colorectal cancer.

Reactivity

Human

Isotype

IgG

Vial size

100 ¦Ìg,1 mg,5 mg,10 mg,25 mg,50 mg,100 mg

Concentration

Bottled at the concentration indicated on the vial.

Storage

Store at -20¡ãC or -80¡ãC. Avoid repeated freeze.

Western blot

Supportive validation

Submitted by

Oursmab (provider)

Main image

Experimental details

Parsatuzumab (Biosimilar Reference Antibody) (EGFL7)-RA0192-Oursmab determined by SDS-PAGE. The purity of the protein is greater than 98%.

ELISA

Supportive validation

Submitted by

Oursmab (provider)

Main image

Experimental details

ELISA plate pre-coated Antigen protein, can bind Parsatuzumab (Biosimilar Reference Antibody) (EGFL7)-RA0192 in a linear range of 0.18¨C15 ng/mL.